echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Shrink tumors by more than 80% AKT targeted protein degradation therapy is expected to treat a variety of cancers

    Shrink tumors by more than 80% AKT targeted protein degradation therapy is expected to treat a variety of cancers

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AKT is an important target related to a variety of cancers


    In this study, scientists used tumor cell lines to screen out protein degradation agents that can target AKT


    The researchers screened an AKT protein degradation agent called M21 and tested its anti-cancer activity in mouse models of breast and prostate cancer


    ▲M21 reduces tumor growth by 90% in a mouse model of prostate cancer (picture source: reference [1])

    The researchers also evaluated which cancers are sensitive to this protein degrading agent


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.